To the Editor: The article by Canellos et al. (Nov. 19 issue)1makes an important contribution to the longstanding controversy2,3about the optimal drug regimen for advanced Hodgkin's disease.On the basis of their investigation, the authors conclude thattreatment with doxorubicin, bleomycin, vinblastine, and dacarbazine(ABVD) is superior to treatment with the older combination ofmechlorethamine, vincristine, procarbazine, and prednisone (MOPP),a conclusion that has been in the wind for some time. Becausea definitive study is likely to define standard practice, thenew investigation deserves close scrutiny.
The most worrisome complication of ABVD therapy is the pulmonarytoxicity, . . . [Full Text of this Article]
References
This article has been cited by other articles:
Tesch, H., Diehl, V., Lathan, B., Hasenclever, D., Sieber, M., Ruffer, U., Engert, A., Franklin, J., Pfreundschuh, M., Schalk, K.P., Schwieder, G., Wulf, G., Dolken, G., Worst, P., Koch, P., Schmitz, N., Bruntsch, U., Tirier, C., Muller, U., Loeffler, M.
(1998). Moderate Dose Escalation for Advanced Stage Hodgkin's Disease Using the Bleomycin, Etoposide, Adriamycin, Cyclophosphamide, Vincristine, Procarbazine, and Prednisone Scheme and Adjuvant Radiotherapy: A Study of the German Hodgkin's Lymphoma Study Group. Blood
92: 4560-4567
[Abstract][Full Text]
Multani, P. S., Grossbard, M. L.
(1996). Staging Laparotomy in the Management of Hodgkin's Disease: Is it Still Necessary?. The Oncologist
1: 41-55
[Abstract][Full Text]